Anuh Pharma Ltd

Q4 FY23Pharmaceuticals & Biotechnology

Anuh Pharma Q4 FY23 earnings call: Revenue & Margins

Q4 FY23 investor presentation: what the company reported on revenue, margins and projects.

Price₹91

Market cap₹937 Cr

P/E21.2

Updated24 Sept 2026

Read4 min read

Based on Anuh Pharma Ltd's Q4 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Operating revenue for the quarter ended 31/03/2023 was Rs. Quarterly EBITDA: Rs.

From Anuh Pharma Ltd's Q4 FY23 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

Operating revenue for the quarter ended 31/03/2023 was Rs. 157.31 Cr, up from Rs. 138.73 Cr in the same quarter of the previous year, showing a year-on-year increase of approximately 13.5%.
For the full FY 2023, operating revenue was Rs. 527.49 Cr compared to Rs. 486.65 Cr in FY 2022, an 8% year-on-year growth.
Export sales increased by about 26.92% from Rs. 228 Cr in FY 2022 to Rs. 289 Cr in FY 2023.

2 more points management made on revenue & sales performance

Profitability & Margins

Quarterly EBITDA: Rs. 15.27 Cr (up 5% QoQ compared to Rs. 14.54 Cr)
Quarterly Operating Profit Margin: 20.29% (slight decrease from 21.16% QoQ)
Quarterly PAT: Rs. 9.62 Cr (up 3% QoQ from Rs. 9.31 Cr)
Year-on-Year (FY 2023 vs FY 2022) figures:
EBITDA: Rs. 57.39 Cr, up 10% from Rs. 52.04 Cr
Operating Revenue: Rs. 114.75 Cr, up 17% from Rs. 98.10 Cr
PAT: Rs. 36.18 Cr, up 18% from Rs. 30.56 Cr
Operating Profit Margin FY23: 21.75% vs 20.16% in FY22

2 more points management made on profitability & margins

See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Planned Capex of Rs 5 Cr for capacity enhancement to support a target growth rate of 20% (Page 7).
Manufacturing capacity at L&L site for corticosteroids enhanced to 12 MTPA (Page 30).
No specific new plant or project timelines detailed; focus on capacity improvements and efficiency.

- Upcoming CEP approval of Gliclazide and Azithromycin aimed at accessing European markets, implying readiness for growth but no explicit capex mentioned (Page 30). - R&D facility: Dedicated 10,000 sq. ft. in-house lab with 16 scientists operational for new product/process development (Page 28). No explicit mention of project status or timelines beyond above points is provided in the presentation.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential

1KRM Ayurveda Ltd₹636 Cr

Rev 1Mar 1

2Accretion Pha.₹226 Cr

Rev 1Mar 2

3₹18.4K Cr

Rev 1Mar 3

4₹6.2K Cr

Rev 1Mar 3

5₹36 Cr

Rev 1Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The presentation does not explicitly mention any fundraising through debt or equity.
There is no direct reference to new borrowings or issuance of equity in the provided content.
Debt to Equity ratios over the years are shown on page 12, indicating some level of stable debt but no indication of recent increase or fresh fundraising:
Debt to Equity (%): 57 (18-19), 47, 35, 58, 56 (22-23)
The financial and operational highlights focus on revenue, profitability, and planned Capex of Rs. 5 Cr. for capacity enhancement but do not link this to any funding source.

2 more points management made on fundraising & capital structure

See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation for Anuh Pharma Ltd. does not explicitly mention order book, order inflow, or pending orders anywhere in the provided pages. The key financial and operational data disclosed include: - FY23 total revenue of Rs 537 Cr, with 8.33% top-line growth over FY22. - EBITDA of Rs 57 Cr in FY23, up 9.6% from FY22. - Segment contributions from Antimalaria, Antibiotic, and Antidiabetic products.

2 more points management made on order book & pipeline

Anuh Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Anuh Pharma Ltd's management said in earlier quarters

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Anuh Pharma Ltd Q4 FY23 results?

Operating revenue for the quarter ended 31/03/2023 was Rs. Quarterly EBITDA: Rs.

What is Anuh Pharma Ltd share price analysis?

Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anuh Pharma Ltd planning capital expenditure?

Planned Capex of Rs 5 Cr for capacity enhancement to support a target growth rate of 20% (Page 7).

Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Revenue & Sales Performance

Profitability & Margins

Capital Expenditure Plans

Top-ranked in Pharmaceuticals & Biotechnology

Fundraising & Capital Structure

Order Book & Pipeline

Anuh Pharma Ltd — Quarterly revenue & net profit

Continue your research

What Anuh Pharma Ltd's management said in earlier quarters

Frequently Asked Questions